BTIG Rates Natera (NTRA) buy, $270 Price Target
BTIG's Mark Massaro keeps a buy rating for Natera, setting a $270 price target, a 2% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
BTIG rated Natera, Inc. ($NTRA) "buy" with a $270 price target on June 23, 2026.
Since the rating, $NTRA is up 15.6% after 1 week, up 12.8% after 1 month and up 67.6% to date (from the $234.76 close on Jun 23, 2026).
NTRA
Natera, Inc.
Key Points
- On June 23, 2026, BTIG's Mark Massaro reiterated a buy rating on Natera, Inc., setting a price target of $270.
- BTIG's $270 price target implies 2% upside from Natera, Inc.'s ($NTRA) current $264.70 share price.
- Natera, Inc. traded at $235.59 on Wednesday, with a market cap of $32.8 billion and a beta of 1.544.
- JPMorgan Chase & Co increased its position in Natera by 532,333 shares, while BlackRock, Inc. reduced its holdings by 182,103 shares.
Get $NTRA trade alerts by text
We text you when insiders, Congress or big funds trade $NTRA. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Natera, Inc. alert may contain errors. Disclosures
BTIG analyst Mark Massaro reiterated his buy rating for Natera, Inc. (NasdaqGS: NTRA) on June 23, 2026. He set a price target of $270, indicating confidence in the company's future prospects. Shares of Natera traded at $235.59 on Wednesday.
BTIG vs. the S&P 500
Hypothetical returns from BTIG's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Natera, Inc.
Several institutional investors have been active in Natera recently. JPMorgan Chase & Co grew its holdings by 532,333 shares, ending with 13,386,667 shares valued at about $2.5 billion, marking a 4.1% increase. Price T Rowe Associates added 1,312,887 shares, bringing its total to 12,184,876 shares worth approximately $2.4 billion, a 12.1% boost. BlackRock, Inc. trimmed its position by 182,103 shares, now holding 10,677,338 shares valued at $2.1 billion, a 1.7% decrease. Vanguard Capital Management opened a new position with 6,008,496 shares, valued at $1.2 billion. Similarly, Vanguard Portfolio Management LLC initiated a stake of 5,644,695 shares, valued at about $1.13 billion.
Natera, Inc. Stock Down 34.6%
Natera, Inc. traded near $235.59 on Wednesday. The company boasts a market cap of approximately $32.8 billion and has a beta of 1.544, indicating higher volatility compared to the market. The stock's 52-week range spans from $131.81 to $256.36. Its 50-day moving average is $207.88, while the 200-day moving average is $206.57. Natera's forward P/E ratio is not meaningful due to its lack of profitability, with an EPS of -$1.62.
$NTRA price target
Natera, Inc. daily closes and this analyst's $270 target. Not advice.
Recent Earnings
Natera reported revenues of $2.5 billion, reflecting a growth of 38.8%. Despite the revenue increase, the company posted a net margin of -9.05% and a return on equity of -15.02%. Investors look forward to the next earnings report, scheduled for August 6, 2026.
Insider Buying and Selling at Natera, Inc.
Recent insider transactions at Natera include planned sales by Sheena Jonathan, who sold 1,500 shares at $219.88 on June 17, 2026, and 3,150 shares at $211.14 on June 15, 2026. Rowan Chapman also sold 2,964 shares at $216.78 on June 16, 2026. Executive Chairman Matthew Rabinowitz sold 50,000 shares at $214.91 on June 15 and another 50,000 shares at $214.03 on June 12, both as part of planned transactions.
Analysts Set New Price Targets
On June 23, 2026, BTIG's Mark Massaro maintained a buy rating for Natera, setting a $270 price target. Earlier in June, RBC Capital reinstated its buy rating with a $275 target, while Goldman Sachs initiated coverage with a hold rating and a $245 target. The consensus among analysts is a buy rating, with an average price target of $260.05 across 20 opinions.
About Natera, Inc.
Natera, Inc., headquartered in Austin, Texas, is a healthcare company specializing in diagnostics and research. It develops and sells molecular testing services, including Signatera for cancer monitoring and Panorama for prenatal screening. The company employs over 6,100 people and is led by CEO Steven Leonard Chapman.
Bottom Line
BTIG's reiterated buy rating on Natera, Inc. reflects continued confidence in the company's potential, despite its current lack of profitability. With a notable presence in the diagnostics sector and active institutional interest, Natera remains a company to watch. Remember, analyst ratings like these are based on past data and market conditions.
Related Filing Alerts
Source: BTIG's rating change on $NTRA (Jun 23, 2026). Written by software, not financial advice. How we make alerts